AIM-PA.TO
Aimia Inc.$22.00
Jun 02, 2026
Market cap
$1.38M
52w range
—
P / E
—
EPS
—
Volume
—
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Aimia Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Poolbeg Pharma shows clinical progress with latest updatesproactiveinvestors.co.uk·Jun 11, 2026
- PAF raises £800,000 to advance Zimbabwe lithium projectproactiveinvestors.co.uk·Jun 11, 2026
- Coastal Africa joins AIM with BP topping up £27m coffersproactiveinvestors.co.uk·Jun 10, 2026
- AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rulesglobenewswire.com·Jun 09, 2026
- AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rulesglobenewswire.com·Jun 09, 2026
- AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancerglobenewswire.com·Jun 08, 2026
- AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancerglobenewswire.com·Jun 08, 2026
- Coiled Therapeutics strengthens its scientific benchproactiveinvestors.co.uk·Jun 08, 2026
Peers
No peer list available for AIM-PA.TO.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|